- Trials with a EudraCT protocol (242)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
242 result(s) found for: Chronic respiratory failure.
Displaying page 4 of 13.
EudraCT Number: 2019-001551-39 | Sponsor Protocol Number: 53718678RSV2005 | Start Date*: 2019-11-14 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-5371... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) SE (Completed) BE (Completed) BG (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000712-33 | Sponsor Protocol Number: 2008/001 | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Medizinische Universität Graz | |||||||||||||
Full Title: Fentanyl for the treatment of dsypnea in patients with chronic heart failure | |||||||||||||
Medical condition: Symptomatic treatment of dyspnea induced by chronic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000883-16 | Sponsor Protocol Number: 200699 | Start Date*: 2014-07-03 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Devlopment Ltd | ||||||||||||||||||
Full Title: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component | ||||||||||||||||||
Medical condition: COPD Subjects with an Asthmatic Component | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) RO (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001160-29 | Sponsor Protocol Number: NAL-II-19-1 | Start Date*: 2019-06-24 | |||||||||||
Sponsor Name:LABORATOIRES SMB S.A | |||||||||||||
Full Title: A single blind, placebo controlled, three period, chronic dosing (6 weeks), multicentre, exploratory study to evaluate the effects of Nacystelyn (20 mg BID and 40 mg BID) on Functional Respiratory ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001468-21 | Sponsor Protocol Number: V1.0 | Start Date*: 2015-09-24 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: Inhaled furosemide for dyspnoea relief in advanced heart failure | |||||||||||||
Medical condition: Advance heart failure - New York Class Association III-IV with ejection fraction <35%. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005849-16 | Sponsor Protocol Number: KIN001-203 | Start Date*: 2021-03-09 | |||||||||||
Sponsor Name:Kinarus AG | |||||||||||||
Full Title: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patient... | |||||||||||||
Medical condition: COVID-19 development in hospitalized patients infected with SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002617-33 | Sponsor Protocol Number: VS01IIa01 | Start Date*: 2022-08-17 | |||||||||||
Sponsor Name:Versantis AG | |||||||||||||
Full Title: A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety and tolerability of VS-01 on top of standard of care, compared to standard of ca... | |||||||||||||
Medical condition: Acute-on-chronic liver failure (ACLF) is characterized by hepatic and extrahepatic organ dysfunction and/or failure and highly activated systemic inflammation. It leads to an accumulation of differ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002213-18 | Sponsor Protocol Number: EDP938-103 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Enanta Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection o... | |||||||||||||
Medical condition: Respiratory syncytial virus (RSV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000603-40 | Sponsor Protocol Number: FER-CARS-04 | Start Date*: 2011-06-20 | ||||||||||||||||
Sponsor Name:Vifor (International) Inc. | ||||||||||||||||||
Full Title: Multicentre, prospective, randomised, 2-arm study to assess the impact of ferric carboxymaltose on exercise capacity in chronic heart failure patients with iron deficiency | ||||||||||||||||||
Medical condition: Iron deficiency in patients with chronic heart failure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) DE (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001194-24 | Sponsor Protocol Number: V3011902 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Veru Inc. | |||||||||||||
Full Title: Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute R... | |||||||||||||
Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002479-33 | Sponsor Protocol Number: R2377 | Start Date*: 2020-03-02 | ||||||||||||||||||||||||||
Sponsor Name:Hull University Teaching Hospitals NHS Trust | ||||||||||||||||||||||||||||
Full Title: A parallel group, double-blind, randomised, placebo-controlled trial comparing the effectiveness and cost effectiveness of low dose oral modified release morphine versus placebo on patient-reported... | ||||||||||||||||||||||||||||
Medical condition: Chronic breathlessness due to cardiac, respiratory disease or cancer. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024283-18 | Sponsor Protocol Number: AF219-006 | Start Date*: 2011-05-20 | |||||||||||
Sponsor Name:Afferent Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects with Chronic Cough | |||||||||||||
Medical condition: Subjects with Chronic Cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004198-41 | Sponsor Protocol Number: UCDCRC/16/003 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL (THE POPART TRIAL) | |||||||||||||
Medical condition: Preterm Infants at risk of respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) SE (Completed) CZ (Completed) PT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001245-13 | Sponsor Protocol Number: 4LB-LEO-P | Start Date*: 2022-03-03 | ||||||||||||||||
Sponsor Name:4Living Biotech SAS | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO) | ||||||||||||||||||
Medical condition: Severe COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) NL (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002858-23 | Sponsor Protocol Number: PI2019_843_0051 | Start Date*: 2019-11-20 |
Sponsor Name:CHU Amiens-Picardie | ||
Full Title: Serratus plain block versus paravertebral block versus serratus plain block and paravertebral block for postoperative pain following thoracoscopic surgery | ||
Medical condition: postoperative pain following thoracoscopic surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001312-30 | Sponsor Protocol Number: FARM9B7LWE | Start Date*: 2013-09-15 |
Sponsor Name:Università di Napoli Federico II | ||
Full Title: Long term effects of selective beta1-adrenoceptor blockade with bisoprolol on hospital readmissions of elderly patients with coexisting heart failure and chronic obstructive pulmonary disease: a mu... | ||
Medical condition: Chronic obstructive pulmonary disease, heart failure | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002308-42 | Sponsor Protocol Number: MK-7264-043 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | |||||||||||||
Full Title: A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough | |||||||||||||
Medical condition: Chronic Cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001357-40 | Sponsor Protocol Number: HDZNRW-KA_006_TB | Start Date*: 2016-11-08 |
Sponsor Name:Klinik für Kardiologie, Herz- und Diabeteszentrum NRW | ||
Full Title: High-Flow-Therapy for the treatment of Cheyne-Stokes-Respiration in chronic heart failure: A randomized, controlled, cross-over trial | ||
Medical condition: Cheyne-Stokes Respiration in chronic heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-004923-34 | Sponsor Protocol Number: RSV-MVA-004 | Start Date*: 2022-07-07 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults ≥60 Years of Age | |||||||||||||
Medical condition: respiratory syncytial virus disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003947-36 | Sponsor Protocol Number: NT2014/Orv/Prot001 | Start Date*: 2015-01-12 | |||||||||||
Sponsor Name:NeRRe Therapeutics Ltd | |||||||||||||
Full Title: Evaluation of orvepitant in an exploratory open-label clinical study in chronic treatment-refractory cough | |||||||||||||
Medical condition: Chronic treatment-refractory cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
